Markets

St. Jude Medical's OPTIS Mobile System in Japan & Europe

St. Jude Medical Inc.STJ recently rolled out the company's OPTIS Mobile System in Japan and Europe. The new product integrates optical coherence tomography (OCT) and angiography co-registration with fractional flow reserve (FFR) technology.

St. Jude's OPTIS Mobile System is designed to increase the efficiency of percutaneous coronary intervention (PCI) procedures through combined OCT and FFR technology. PCI, or coronary angioplasty, is a non-surgical procedure. It is designed to alleviate coronary blood flow blockages and restore blood flow to the heart. Earlier, physicians relied on angiography or intravascular ultrasound to guide PCI.

The imaging improvements that come with the new product allows physicians to see complex cardiac anatomy in a more detailed fashion, which eventually helps them to perform the procedure better. St. Jude Medical PressureWire FFR measurement technology provides comprehensive coronary hemodynamic (circulatory) data during PCI procedures, which help to improve results while reducing health care costs.

The advantages of using OCT and FFR technology has been previously demonstrated by various clinical data. While the ILUMIEN I and ILUMIEN II clinical studies hinted at the benefits of OCT imaging, the St. Jude sponsored FAME body of evidence established that FFR technology helps improve efficiency of PCI procedures.

We believe St. Jude's OPTIS Mobile System will provide improved options to physicians performing PCI procedures with its combination of OCT and FFR. Hence we are optimistic that the new product will help increase the company's existing customer base, which in turn, will improve revenues.

According to a research report by MarketsandMarkets, the interventional cardiology and peripheral vascular devices market is expected to reach $26.72 billion by 2019. We believe St. Jude's focus on rolling out innovative products will help the company gain a significant share of this growing market.

Zacks Rank and Key Picks

Currently, St. Jude has a Zacks Rank #4 (Sell). Better-ranked stocks in the medical sector are Abiomed ABMD , Exactech EXAC and Luminex LMNX . All the stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LUMINEX CORP (LMNX): Free Stock Analysis Report

ABIOMED INC (ABMD): Free Stock Analysis Report

ST JUDE MEDICAL (STJ): Free Stock Analysis Report

EXACTECH INC (EXAC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD LMNX

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More